Progesterone receptor modulators for endometriosis

In: Cochrane Database of Systematic Reviews · 2026 · vol. 2026(9) · doi:10.1002/14651858.cd009881.pub3 · W7213295793
OA: closed CC0
⚙ AI-generated summary by qwen3.7-flash+body, 2026-10-30 ⓘ

This Cochrane review assessed progesterone receptor modulators for endometriosis, finding low-certainty evidence that mifepristone may improve dysmenorrhoea but increases hot flushes compared to placebo.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-30 · read from full text ⓘ

This Cochrane review updates previous evidence on the effectiveness and safety of progesterone receptor modulators for managing symptomatic endometriosis in women. The analysis included nine randomized controlled trials comparing agents such as mifepristone, gestrinone, and asoprisnil against placebos or other medical treatments like danazol and GnRH analogues. The authors found low to very low certainty evidence that mifepristone may improve dysmenorrhoea but potentially increases hot flushes, while gestrinone showed mixed results compared to leuprorelin regarding pain relief and side effects. This paper is centrally about endometriosis — specifically evaluating pharmacological management options using progesterone receptor modulators.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 8,397 characters · extracted from oa-html · 3 sections · click to expand

Abstract

Rationale: Endometriosis is defined as the presence of endometrium-like tissue developing outside the uterine cavity. This condition is oestrogen-dependent and thus is seen primarily during the reproductive years. Owing to their antiproliferative effects on the endometrium, progesterone receptor modulators (PRMs) have been advocated for the treatment of endometriosis. This is an update of a Cochrane review previously published in 2017.

Objectives

To assess the effectiveness and safety of progesterone receptor modulators (PRMs) in the management of endometriosis. Search methods: To identify studies, we searched online sources, including the Cochrane Gynaecology and Fertility (CGF) Group trials register, CENTRAL, MEDLINE, Embase, PsycINFO, ClinicalTrials.gov and the WHO (World Health Organization) trial registry up to 16 April 2026. We also checked reference lists and contacted study authors and experts. Eligibility criteria: We included randomised controlled trials (RCTs) comparing PRMs with placebo, no treatment or other medical treatment, in women with symptomatic endometriosis. Outcomes: Our critical outcomes were overall pain; improvement in the most troublesome symptom, including dysmenorrhoea and dyspareunia; and adverse events resulting from the PRM intervention. Our important outcomes included quality of life (QoL) and patient satisfaction with treatment. Risk of bias: We used the Cochrane tool RoB 2 to assess the risk of bias in the outcomes of this review. Synthesis methods: Two review authors independently assessed studies against the inclusion criteria, extracted data and assessed risk of bias, consulting a third review author where required. We analysed dichotomous outcomes using Mantel-Haenszel odds ratios (ORs), 95% confidence intervals (CIs) and the fixed-effect model. We analysed continuous outcomes using the mean difference (MD) between groups, presented with 95% CIs. We employed the GRADE approach to assess the certainty of the evidence as high, moderate, low or very low. Included studies: No new studies were eligible for inclusion in this update. Of the nine studies (922 women) already included in the review, two compared mifepristone versus placebo or compared different doses of mifepristone, and four either compared gestrinone versus danazol, gestrinone versus gonadotropin-releasing hormone (GnRH) analogues or compared different doses of gestrinone. One study compared asoprisnil versus placebo. The asoprisnil study did not provide extractable numerical data and was included in the narrative synthesis only. Two of the studies did not report any of the review's prespecified outcomes. Synthesis of results: Certainty of the evidence We judged the certainty of evidence as low to very low. The main limitations of the evidence were serious risk of bias (associated with poor reporting of methods and high or unclear rates of attrition), very serious imprecision (associated with low event rates and wide confidence intervals, with some large effect estimates) and serious indirectness (outcomes assessed in selected subgroups). PRM versus placebo Mifepristone versus placebo These results are based on one study (360 participants) that measured outcomes after three months. The study did not report overall pain. At three months, mifepristone may improve dysmenorrhoea (OR 0.07, 95% CI 0.03 to 0.15; 1 study, 342 participants; low-certainty evidence), suggesting that if 40% of women taking placebo experience dysmenorrhoea, then between 3% and 10% of women taking mifepristone will do so. We are uncertain whether mifepristone improves dyspareunia (OR 0.23, 95% CI 0.10 to 0.51; 1 study, 223 participants; very low-certainty evidence). However, mifepristone may increase hot flushes (OR 28.79, 95% CI 3.93 to 210.73; 1 study, 360 participants; low-certainty evidence). Mifepristone may make little or no difference after three months of treatment to the prevalence of nausea (OR 1.72, 95% CI 0.20 to 15.03; 1 study, 360 participants; low-certainty evidence). PRM versus other medical treatment Gestrinone versus danazol These results are based on two studies (302 participants) that measured outcomes after six months. We are uncertain of the effects of gestrinone relative to danazol on the improvement of overall pain (dichotomous outcome: participants reporting no or mild pelvic pain counted as 'improved') (OR 0.47, 95% CI 0.04 to 5.70; 1 study, 38 participants), dysmenorrhoea (Not estimable; 1 study, 38 participants), or dyspareunia (OR 1.00, 95% CI 0.13 to 7.94; 1 study, 38 participants (all very low-certainty evidence). We are uncertain about the effects of gestrinone relative to danazol on hot flushes (OR 0.79, 95% CI 0.50 to 1.26; 2 studies, 302 participants; very low-certainty evidence). There may be little or no difference between gestrinone and danazol in rates of nausea (OR 1.36, 95% CI 0.84 to 2.19; 2 studies, 302 participants; low-certainty evidence). Gestrinone versus a GnRH analogue (leuprorelin) These results are based on one study (55 participants) that measured outcomes after six months. There may be little to no difference between gestrinone and leuprorelin in non-menstrual pain (MD -0.41, 95% CI -1.76 to 0.94; 1 study, 55 participants; low-certainty evidence). Women taking gestrinone may have higher dysmenorrhoea scores than those taking leuprorelin (MD 0.82, 95% CI 0.15 to 1.49; 1 study, 55 participants; low-certainty evidence), but gestrinone may improve dyspareunia more than leuprorelin (MD -1.16, 95% CI -2.08 to -0.24; 1 study, 52 participants; low-certainty evidence). There may be lower rates of hot flushes with gestrinone than leuprorelin (OR 0.20, 95% CI 0.06 to 0.63; 1 study, 55 participants; low-certainty evidence). There may be little or no difference between gestrinone and leuprorelin in rates of nausea (OR 1.04, 95% CI 0.06 to 17.49; 1 study, 55 participants; low-certainty evidence). Authors' conclusions: Mifepristone may improve dysmenorrhoea in women with endometriosis, but it might increase the prevalence of adverse events, such as hot flushes. The evidence is very uncertain regarding its effect on dyspareunia. Gestrinone may be less effective than leuprorelin in treating dysmenorrhoea, but it may improve dyspareunia. It may be associated with lower rates of hot flushes and similar rates of nausea. We are uncertain about the effect of gestrinone compared to danazol. We found insufficient evidence to permit firm conclusions about the safety and effectiveness of other progesterone receptor modulators. Funding: This Cochrane review had no dedicated funding. Registration: Protocol (2012) DOI: 10.1002/14651858.CD009881 Review (2017) DOI: 10.1002/14651858.CD009881.pub2. Copyright © 2026 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Conflict of interest statement ALG has no interests to declare. TG has no interests to declare. ENA has no interests to declare. CMB has received research support from Bayer and Serac Life Sciences; consultancy fees from Sumitovant, Gedeon Richter, ObsEva, Roche Diagnostics, Theramex, Apical and Gesynta. All funds went to the University of Oxford. Update of - Progesterone receptor modulators for endometriosis.Cochrane Database Syst Rev. 2017 Jul 25;7(7):CD009881. doi: 10.1002/14651858.CD009881.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2026 Sep 16;9:CD009881. doi: 10.1002/14651858.CD009881.pub3. PMID: 28742263 Free PMC article. Updated.

References

- - Berek JS. Endometriosis. In: Berek & Novak's Gynecology. 16th edition. Baltimore, MD: Lippincott Williams & Wilkins, 2019. - - Zondervan KT, Becker CM, Missmer SA. Endometriosis. New England Journal of Medicine 2020;382(13):1244-56. [DOI: doi 10.1056/NEJMra1810764] - PubMed - - Eskenazi B, Warner M. Epidemiology of endometriosis. Obstetrics and Gynecology Clinics of North America 1997;24:235-58. - PubMed - - Goldstein DP, DeCholnoky C, Emans SJ, Leventhal JM. Laparoscopy in the diagnosis and management of pelvic pain in adolescents. Journal of Reproductive Medicine 1980;24:251-6. - PubMed Publication types MeSH terms Substances LinkOut - more resources Full Text Sources Medical Research Materials Miscellaneous

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (56)

Source provenance

openalex
last seen: 2026-09-17T06:03:51.838633+00:00
unpaywall
last seen: 2026-10-09T06:36:44.367587+00:00
License: CC0 · commercial use OK